Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
5
Enerpac Tool
EPAC
US OptionsDetailed Quotes
REGN250502C590000
- 16.50
- +11.18+210.15%
15min DelayClose May 2 16:00 ET
19.82High16.50Low
19.50Open5.32Pre Close26 Volume121 Open Interest590.00Strike Price50.15KTurnover0.00%IV0.15%PremiumMay 2, 2025Expiry Date15.61Intrinsic Value100Multiplier0DDays to Expiry0.89Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma39.45Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Regeneron Pharmaceuticals Newsroom
Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $810
Regeneron Pharma Is Maintained at Buy by Guggenheim
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $587 to $940
Regeneron (REGN) Gets a Buy From Evercore ISI
Guggenheim Cuts Regeneron Pharmaceuticals' Price Target to $810 From $940
Regeneron Pharma Is Maintained at Overweight by Wells Fargo
Evercore ISI Cuts Regeneron Pharmaceuticals' Price Target to $900 From $950
Wells Fargo Cuts Regeneron Pharmaceuticals' Price Target to $700 From $750
Jefferies Adjusts Regeneron Pharmaceuticals' Price Target to $914 Rom $936, Keeps Buy Rating
Regeneron Pharmaceuticals Analyst Ratings
UBS Adjusts Price Target on Regeneron Pharmaceuticals to $633 From $768, Maintains Neutral Rating
RBC Capital Sticks to Their Buy Rating for Regeneron (REGN)
BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Sell Rating, Maintains Target Price $547
Oppenheimer Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $900
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $800
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $925
BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Sell Rating, Maintains Target Price $547
Baird Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Cuts Target Price to $652
Regeneron Pharma Is Maintained at Neutral by Baird
Regeneron Pharma Price Target Cut to $652.00/Share From $759.00 by Baird
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now